264 related articles for article (PubMed ID: 32058125)
1. A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture.
Hsu CL; Chen HM; Chen HJ; Chou MY; Wang YC; Hsu YH; Liang CK; Chu CS
Arch Gerontol Geriatr; 2020; 88():104021. PubMed ID: 32058125
[TBL] [Abstract][Full Text] [Related]
2. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
3. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
[TBL] [Abstract][Full Text] [Related]
4. Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures.
Lin SY; Chen WJ; Ku CK; Chen YM; Chen CH; Chien LN
J Clin Endocrinol Metab; 2023 Dec; 109(1):e200-e208. PubMed ID: 37526298
[TBL] [Abstract][Full Text] [Related]
5. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
[TBL] [Abstract][Full Text] [Related]
6. Duration of osteoporosis treatment to reduce the risk of subsequent osteoporotic fracture and all-cause mortality in elderly hip fracture patients in a Korean real-world study.
Lee SJ; Cho M; Lee H; Lim H; Lee JH
Arch Osteoporos; 2024 Jan; 19(1):9. PubMed ID: 38198067
[TBL] [Abstract][Full Text] [Related]
7. Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study.
Wu CH; Li CC; Hsu YH; Liang FW; Chang YF; Hwang JS
J Clin Endocrinol Metab; 2023 Mar; 108(4):827-833. PubMed ID: 36317591
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
9. Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study.
Tai TW; Li CC; Huang CF; Chan WP; Wu CH
Bone; 2022 Jan; 154():116216. PubMed ID: 34571203
[TBL] [Abstract][Full Text] [Related]
10. Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore.
Chau YT; Nashi N; Law LS; Goh RKH; Choo SX; Seetharaman SK
Arch Osteoporos; 2020 Sep; 15(1):141. PubMed ID: 32918196
[TBL] [Abstract][Full Text] [Related]
11. The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study.
Li CC; Hsu JC; Liang FW; Chang YF; Chiu CJ; Wu CH
Aging (Albany NY); 2022 Mar; 14(5):2239-2251. PubMed ID: 35232893
[TBL] [Abstract][Full Text] [Related]
12. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.
Degli Esposti L; Girardi A; Saragoni S; Sella S; Andretta M; Rossini M; Giannini S;
Endocrine; 2019 May; 64(2):367-377. PubMed ID: 30515678
[TBL] [Abstract][Full Text] [Related]
13. Decreased Mortality and Subsequent Fracture Risk in Patients With a Major and Hip Fracture After the Introduction of a Fracture Liaison Service: A 3-Year Follow-Up Survey.
Vranken L; de Bruin IJA; Driessen AHM; Geusens PPM; Eisman JA; Center JR; van der Velde RY; Janzing HMJ; Kaarsemaker S; van den Bergh JP; Wyers CE
J Bone Miner Res; 2022 Oct; 37(10):2025-2032. PubMed ID: 36087016
[TBL] [Abstract][Full Text] [Related]
14. Exploring the osteoporosis treatment gap after fragility hip fracture at a Tertiary University Medical Center in Thailand.
Mahaisavariya C; Vanitcharoenkul E; Kitcharanant N; Chotiyarnwong P; Unnanuntana A
BMC Geriatr; 2023 Feb; 23(1):70. PubMed ID: 36737708
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of non-treatment and non-persistence to osteoporosis medication after fragility hip fractures at 3 years after discharge: a multicentre, prospective cohort study in the northern Kyushu district of Japan.
Kanahori M; Matsumoto Y; Fujiwara T; Kimura A; Tsutsui T; Arisumi S; Oyamada A; Ohishi M; Ikuta K; Tsuchiya K; Tayama N; Tomari S; Miyahara H; Mae T; Hara T; Saito T; Arizono T; Kaji K; Mawatari T; Fujiwara M; Takasaki M; Shin K; Ninomiya K; Nakaie K; Antoku Y; Iwamoto Y; Nakashima Y
Arch Osteoporos; 2021 Sep; 16(1):132. PubMed ID: 34515859
[TBL] [Abstract][Full Text] [Related]
17. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
18. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis.
Merlijn T; Swart KMA; van der Horst HE; Netelenbos JC; Elders PJM
Osteoporos Int; 2020 Feb; 31(2):251-257. PubMed ID: 31838551
[TBL] [Abstract][Full Text] [Related]
19. Application of an in-hospital, surgeon-led anti-osteoporotic medication algorithm in patients with hip fractures improves persistence to medication and can prevent the second fragility fracture.
Daskalakis II; Kritsotakis EI; Karantanas AH; Kontakis GM; Bastian JD; Tosounidis TH
Arch Orthop Trauma Surg; 2024 Feb; 144(2):683-692. PubMed ID: 38044337
[TBL] [Abstract][Full Text] [Related]
20. Mortality and complications after hip fracture among elderly patients undergoing hemodialysis.
Lin JC; Liang WM
BMC Nephrol; 2015 Jul; 16():100. PubMed ID: 26149489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
